Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhEPO to reduce top-up transfusions in neonates with hemolytic disease of the newborn
2010-023955-27Phase 3Active
- Sponsor
- Leiden University Medical Center
- Start
- May 2011
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of epoetin beta in Erythroblastosis fetalis (HDFN) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Absolute reduction of 50% of top-up transfusions, Number of top-up transfusions required per infant up to 3 months of life and 1 more. Started May 2011; status: active.
02
Drugs
epoetin beta
03
Conditions
Erythroblastosis fetalis (HDFN)
Beyond the preview
Go deeper on 2010-023955-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023955-27.